The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses
Authors:
- Naotoshi SugimotoNSNaotoshi Sugimoto
- Shingo NouraSNShingo Noura
- Takeshi KatoTKTakeshi Kato
- Shinichi YoshiokaSYShinichi Yoshioka
- Taishi HataTHTaishi Hata
- Atsushi NaitoANAtsushi Naito
- Mitsuyoshi TeiMTMitsuyoshi Tei
- Hiroshi TamagawaHTHiroshi Tamagawa
- Takamichi KomoriTKTakamichi Komori
- Yoshihito IdeYIYoshihito Ide
- Takayuki FukuzakiTFTakayuki Fukuzaki
- Katsuki DannoKDKatsuki Danno
Open Access
Abstract
Background: FOLFIRI (5-FU + leucovorin + irinotecan) plus ramucirumab is one of the standards in second-line metastatic colorectal cancer (CRC) patients progressing after treatment with oxaliplatin/fluoropyrimidine with bevacizumab, but there is no evidence on its efficacy without prior bevacizumab. Moreover, VEGF-D has not been confirmed as a predictive biomarker for ramucirumab’s efficacy, either. Methods: The RAINCLOUD study was a multicenter, single-arm, phase II trial conducted in Japan. Patients with recurrent CRC pretreated with fluoropyrimidine and oxaliplatin without bevacizumab were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints measured were overall survival (OS), overall response rate (ORR), and safety. Results: A total of 48 patients were enrolled from 15 sites between September 2017 and September 2020. Their median age was 63.5 years (25~77), 20.1% had a right-sided tumor, and 68.8% had RAS-mutant cancer. The median PFS was 8.9 months (90% CI: 6.3–11.8), so the primary endpoint was met. Their median OS and ORR were 22.3 months (95% CI: 17.4-NA) and 41.7% (95% CI: 4.9–7.6), respectively. An incidence of grade 3/4 adverse events that reached over 5% applied to neutropenia (44%), leucopenia (10%), and hypertension (8%). In the biomarker analysis, the serum VEGF-D levels post-treatment were higher than those pre-treatment, but the PFS in those with high VEGF-D levels trended towards being worse than that in those with low VEGF-D (7.6M/5.6M (p = 0.095; HR: 0.56)). Instead, those with low TSP-2 had a better PFS than those with high TSP-2 (7.5M/4.3M (p = 0.022; HR: 0.45)). Conclusions: Our data suggested that FOLFIRI plus ramucirumab was effective and tolerable for CRC refractory to fluoropyrimidine and oxaliplatin without anti-angiogenesis. Serum VEGF-D levels may not be predictive but TSP-2 may be a potential prognostic biomarker for ramucirumab’s efficacy.Keywords
Funding Information
- Eli Lilly Japan KK
This publication has 30 references indexed in Scilit:
- 463P Impact of plasma angiogenesis factors on the efficacy of 2nd-line chemotherapy combined with biologics in metastatic colorectal cancer (mCRC): Early efficacy results from GI-SCREEN CRC Ukit studyAnnals of Oncology, 2021
- Effects of thrombospondin-4 on pro-inflammatory phenotype differentiation and apoptosis in macrophagesCell Death & Disease, 2020
- Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancerBioscience Reports, 2019
- THBS2 is a Potential Prognostic Biomarker in Colorectal CancerScientific Reports, 2016
- Secretome Profiling of Primary Cells Reveals That THBS2 Is a Salivary Biomarker of Oral Cavity Squamous Cell CarcinomaJournal of Proteome Research, 2014
- Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trialEuropean Journal of Cancer, 2014
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803European Journal of Cancer, 2011
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)The Lancet Oncology, 2010
- Thrombospondin modules and angiogenesisThe International Journal of Biochemistry & Cell Biology, 2004
- Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trialThe Lancet, 2000